CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells
Shuchang Zhou, Weiwei Lin, Xiong Jin, Rui Niu, Zheng Yuan, Tianran Chai, Qi Zhang, Meixia Guo, Sung Soo Kim, Meichen Liu, Yilin Deng, Jong Bae Park, Sun Il Choi, Bingyang Shi, Jinlong Yin · 2024
Read CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells by Shuchang Zhou, Weiwei Lin, Xiong Jin, Rui Niu, Zheng Yuan, Tianran Chai, Qi Zhang, Meixia Guo, Sung Soo Kim, Meichen Liu, Yilin Deng, Jong Bae Park, Sun Il Choi, Bingyang Shi, Jinlong Yin (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11722114.txt.
Description
Glioblastoma's stem cells seed its regrowth, and a surface marker that flags them could aim immune therapy precisely. Shuchang Zhou and fourteen co-authors screen antibodies in 2024 and land on CD97, a protein present on every patient derived stem cell line they checked. Silencing it drains the cells' ability to renew themselves and grow tumors.
The protein works through a growth circuit whose blocking also stalls the stem cells. The team then built immune cells of a helper kind, armed with a receptor for CD97, and the cells killed stem cells in dishes and lengthened survival in mice. The authors propose CD97 as a target worth clinical pursuit. A therapy aimed at the seed, they argue, beats mowing the tumor.
Catalog record
| CREATOR | Shuchang Zhou, Weiwei Lin, Xiong Jin, Rui Niu, Zheng Yuan, Tianran Chai, Qi Zhang, Meixia Guo, Sung Soo Kim, Meichen Liu, Yilin Deng, Jong Bae Park, Sun Il Choi, Bingyang Shi, Jinlong Yin |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 104 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |